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From the 
President 
The search for 
the Chairperson 
of the Department of Surgery 
continues. As you may know, Dr. 
Robert Bower declined the position. 
We all appreciate Walter Okunski's 
dedication and commitment to the 
Department of Surgery and the 
institution, and thank him for agreeing 
to continue as the Chairperson, 
Department of Surgery, while this 
search continues. 
The Search Committee for the Vice 
President for Clinical Services has 
reviewed the· CV' s of four potential 
candidates for that position. We have, 
however, hired a new consultant, John 
Lloyd of Witt/Kieffer, to assist us in 
this important search. We will be 
reviewing other potential candidates in 
the next few weeks. 
The search for the COO has been 
progressing well. Two excellent 
candidates have been identified and are 
in the process of further evaluations. 
Also, Michael Kaufmann, M.D., is 
chairing a committee searching for the 
Chairperson of Community Health and 
Health Studies. This represents an 
amalgam of the Research Department 
and Community Health. 
Work on the PHO is moving forward 
at an accelerated pace. Larry Levitt, 
M.D., as Chairperson of the Care 
Management Committee, has been 
tackling the difficult assignment of care 
management with intelligence, 
industry, and enthusiasm. We see this 
aspect of our managed care program as 
vital to the success of our whole PHO 
effort. Larry is going to need our 
assistance in bringing this to fruition 
and thus providing a great plan. Care 
Management should be the means to 
align the intereSts of the physicians and 
hospital within the PHO. 
Best wishes, 
Ji:: Carulio, M.D. 
President, M~cal Staff 
At-Large Members Needed for Medical Executive 
Committee 
The Medical Staff Nominating 
Committee is soliciting nominations for 
four at-large seats, each for a three-
year term beginning July 1, 1994, on 
the Medical Executive Committee. 
Nominations should be submitted in 
writing to John E. Castaldo, M.D., 
Chairman of the Nominating 
Committee, via the Medical Staff 
Services Office, Cedar Crest & 1-78, 
or verbally to Joseph A. Candia, 
M.D., Medical Staff President, John 
Jaffe, M.D., Past President, Medical 
Staff, or John W. Hart, Vice President. 
All nominations must be submitted 
prior to June 1, 1994. 
If you have any questions regarding 
this issue, please contact Dr. Castaldo 
or Mr. Hart at 402-8900. 
Medical Staff Services Relocates 
In order to provide room for the new 
ExpressCare service of the Emergency 
Department, Medical Staff Services 
(Cedar Crest & 1-78) was recently 
temporarily relocated to the second 
floor of the General Services Building. 
Individuals effected by the move 
include: 
• Joseph A. Candio, M.D.-
President, Medical Staff 
• John W. Hart - Vice President, 
Medical Staff Services 
• Terri L. Kraft - Executive 
Secretary 
• Sally Roessler - Executive Secretary 
The main number for this location is 
402-8900. 
The remaining Medical Staff 
Services/Physician Relations personnel 
located in the satellite office at 1243 S. 
Cedar Crest Boulevard include: 
Medical Sttiff Services - 402-9850 
• Rita Mest, Medical Staff 
Coordinator 
• Eileen Jobst, Medical Staff Secretary 
• Elizabeth Ehnot, Secretary 
Physicilln Relations Representlltives 
• Patricia Skrovanek, Senior Physician 
Relations Representative - 402-9859 
• Maria Kammetler - 402-9857 
• Janet M. Laudenslager - 402-9853 








There have been many questions 
recently regarding the preferred culture 
containers in which to submit 
specimens for culture. The following 
are guidelines for specimen collection 
container usage: 
• Wounds (collected from a site 
where NO fluid or tissue can be 
collected) 
a. Submit in a Culturette for 
aerobic culture 
b. Submit in a Culturette AND an 
Anaerobic Specimen Collector 
for an anaerobic culture 
c. A Culturette is needed for each 
type of culture request 
e.g. 1 culturette for aerobic 
culture 
• Fluids 
1 culturette for fungus 
culture 
1 culturette for TB 
(Mycobacterial culture) 
a. A fluid is PREFERABLE to a 
specimen collected on a swab. 
It can be concentrated to 
increase the likelihood of 
recovering the pathogen. 
b. DO NOT PUT FLUIDS IN 
CULTURETTES. Place fluids 
in Port-a-cul vials for anaerobic 
culture or in red top vacutainers 
for aerobic culture. Wipe 
rubber stoppers before 
inoculating with the specimen. 
NOTE: Port-a-cul vials should 
be stocked by SPD in all clean 
utility rooms. 
c. Fluids should not be placed in 
culturettes for the following 
reasons: 
o Culturettes are NOT leak-
proof containers. The specimen 
can become contaminated if it 
leaks out of the culturette. 
How do you interpret a 
Coagulase negative 
Staphylococcus spp. isolated 
from a fluid that was placed in 
a culturette and leaked? 
Contaminate or Pathogen?? 
o The fluid soaks into the 
cotton pledget at the bottom of 
the culturette trapping the 
bacteria again giving erroneous 
results. 
o If the fluid leaks out and 
contaminates the outside of the 
culturette, it presents a hazard 
to the person transporting the 
fluid and to the technologist 
working with the specimen. 
• Tissues 
a. Tissues are PREFERABLE to a 
specimen collected on a swab. 
b. Place tissues in a sterile cup and 
transport immediately to 
Microbiology. 
Please remember culture results are 
only as good as the specimen received 
by the lab. Specimens must be 
representative of the site of infection. 
Please keep these guidelines on hand 
and refer to them when there is a 
question on collection and transport of 
specimens. You may also refer to the 
Laboratory Handbook for a complete 
listing of specimens and their transport 
requirements. 
If you have any questions, please 
contact Georgia Colasante, Supervisor, 
Microbiology, at 402-8190. 
Continued on Page 4 
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StwndWng ()rders 
An audit conducted last summer by the 
Clinical Laboratory identified an 
opportunity for savings by eliminating 
repetitive normal testing. Nearly all 
this testing is the result of standing 
orders that are not time limited, e.g., 
CBC, Chern 7 daily. 
At its March meeting, the Medical 
Executive Committee approved a 
policy that prohibits standing orders 
except where they are a part of a 
clinical department-approved clinical 
pathway or protocol. 
This policy became effective on April 
21, 1994. Thus, any orders which are 
not time limited, such as CBC daily, 
will result in a reminder being placed 
on the patient's chart requesting that 
the physician ordering the test time 
Helpful Hints 
Tmnscription 
When dictating difficult words and/ or 
new drugs, Transcription Services 
would appreciate if you would spell 
these words. This will help avoid 
blank spaces in the reports. 
At the time of dictation of operative 
reports, please include date of surgery, 
surgeons, pre-operative and post-
operative diagnoses. 
Coding 
The following are some. common 
conditions which are not consistently 
documented in the medical record. 
limit his/her order. The order, as 
written, will be honored for 48 hours 
to give ample time for the time 
limitation to be added to the test order. 
The following are examples of time 
limited orders: 
• CBC daily times 3 
• BUN Creatinine Monday, 
Wednesday, Friday while patient on 
Gentamicin 
• Blood cultures times 2, one hour 
apart 
• Chest x-ray this a.m. 
Your attention and adherence to this 
policy is greatly appreciated. If you 
have any questions, please contact 
David G. Beckwith, Ph.D., 
Administrator and Clinical Director, . 
Health Network Laboratories, at 
402-8157. 
Accurate data is vital for quality 
assurance, managed care contracts, as 
well as reimbursement. Additions to 
the list will be provided regularly to 






Urinary tract infection (UTI) 
Pyuria 
Urinary retention 
Blood loss anemia (acute or chronic) 
Thrombocytopenia 





News from Research 
Research Advisory 
Committee - Request for 
Proposals 
The Research Advisory Committee 
(RAC) meets bi-monthly to review 
clinical/ epidemiological research 
proposals (requests for funding) 
submitted by the Medical and 
Professional staff of Lehigh Valley 
Hospital. 
All proposals must be submitted to the 
Research Department for review three 
weeks before the next scheduled RAC 
meeting on June 16. All proposals 
submitted by May 25 will be reviewed 
by the Research Department before 
being placed on the RAC agenda. 
For more information or proposal 
guidelines, contact James F. Reed ill, 
Ph.D., Director of Research, at 
402-8889. 
Calls for Abstracts 
A call for abstracts has been issued by 
the following organizations: 
• The American College of Cardiology 
for the 44th Annual Scientific Session 
to be held on March 19, 1995 in New 
Orleans, La. Submission due date is 
sq)tember 9, 1994. 
• The American Society of 
Nephrology for the 27th Annual 
Meeting to be held on October 26, 
1994 in Orlando, Fla. Submission due 
date is June 24, 1994. 
• The Harvard School of Public 
Health for the Second International 
Conference on Dietary Assessment to 
be held on January 24, 1995 in Boston, 
Mass. Submission due date is July 15, 
1994. 
• The Society for Medical Decision 
Making for the 16th Annual Meeting to 
be held on October 16, 1994 in 
Cleveland, Ohio. Submission due date 
is June 1, 1994. 
For instructions, forms, and further 
information, please contact Kathleen 
Moser in the Research Department at 
402-8747. 
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News from the Office of Education 
Category 2 CME 
All physicians in Pennsylvania must 
participate in Continuing Medical 
Education (CME) activities sufficient 
to (a) fulfill the requirements of the 
AMA Physician's Recognition Award 
(PRA ), or (b) fulfill the requirements 
of the Pennsylvania Medical Society. 
These requirements are slightly 
different, but each require participation 
in a minimum of 50 hours of CME 
each year, of which up to 30 hours 
may be designated Category 2. 
Category 2 CME activities include 
clinical consultations contributing to 
the physicians education, QA/QC 
activities, teaching, journal clubs, self 
assessment examinations and reviews, 
computer based learning activities, 
journal or book publications, or 
attending programs designated as 
acceptable for Category 2 education. 
Reading medical journals is not an 
acceptable activity for Category 2 
designation; it is assumed that all 
physicians read the medical literature 
regularly. 
Physicians are responsible for 
cataloging their own Category 2 
activities. 
Only organizations accredited to give 
Category 1 credit can authorize 
programs to advertise that programs 
fulfill the requirements for Category 2 
credit. In the Lehigh Valley, the 
Lehigh Valley Area Health Education 
Center is accredited by the 
Pennsylvania Medical Society to 
approve programs for CME Category 1 
credit. 
New Specialty Bed Contract Signed 
A new three-year specialty bed contract 
waS recently signed with Kinetic 
Concepts, International (KCI) which 
will go into effect on June 1, 1994. 
The selection of this company was 
based on its ability to provide a full 
line of specialty beds and specialty 
mattresses which will best meet the 
needs of our patients. 
These specialty products are used for 
patients who are at high risk for skin 
breakdown, patients with stage 3 or 4 
pressure ulcers who cannot be 
satisfactorily positioned off of the 
ulcers, and patients who are morbidly 
obese who cannot be managed on our 
regular hospital bed and mattress. In 
addition, specialty products that 
provide kinetic therapy and/or lateral 
rotation are used for trauma and 
critically ill patients with unstable 
spines and patients who have or are at 
high risk for developing pneumonia. 
For more information about these 
specialty products, contact Carol 
Balcavage, Coordinator, Enterostomal 
Therapy, at 402-8634. 
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Lehigh Magnetic Imaging Center Begins Renovations 
Recently, Lehigh Magnetic Imaging 
Center broke ground for an expansion 
and renovation project which is 
expected to continue over the next 
several months. 
Upon completion of the construction 
project, patients will be served in a 
more pleasant and efficient 
environment with a new entrance, new 
waiting room and reception areas, a 
dedicated inpatient holding area 
offering privacy for those who are ill, 
and an increased number of private 
dressing rooms. This venture will also 
include a dedicated room for the use of 
pediatric patients who require a quiet 
place for sedation. 
Discount Lodging Program 
A special discount lodging program has 
been arranged with several area motels 
for out-of-town relatives and friends of 
patients at Lehigh Valley Hospital. 
This program is especially directed at 
visitors of hospital patients who enter 
the hospital through non-routine 
admissions, such as the Emergency 
Department or Shock/Trauma Unit. 
The following establishments have 
agreed to participate in this program: 
• Comfort Suites 
3712 Hamilton Boulevard 
Allentown 
• Days Inn 
Routes 22 and 309 
Allentown 
In light of all the activity during 
construction, patient parking has been 
relocated until the project is complete. 
Patients for Lehigh Magnetic Imaging 
Center (LMIC) should now park in the 
area directly opposite the entrance to 
the 1230 and 1240 buildings. Please 
note, however, LMIC patients are 
cautioned not to park in the 
"Handicapped Only" parking spaces 
unless authorized to do so. Others will 
·be ticketed. 
Your cooperation in communicating 
these changes to your patients is very 
much appreciated. 
• EconoLodge 
2115 Downeyflake Lane 
Allentown 
• The Allentown Hilton 
904 Hamilton Mall 
Allentown 
• Holiday Inn 
Fogelsville 
In addition to discounted rates, some of 
the establishments will provide 
transportation to either hospital site. 
For more information or a copy of the 
brochure which describes the program, 
contact Charlotte Gross, Lehigh Valley 
Health Services, at 402-7450. 
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Pool Trust News 
At their April 8 meeting, the Dorothy 
Rider Pool Health Care Trustees 
agreed to provide up to $12,000 to 
support four consultants to Lehigh 
Valley Hospital to assist in the 
recruitment process for a Chairperson 
for Community Health and Health 
Studies. These consultants will act as 
advisors to the hospital, spending two 
days each in this process, while 
Congratulations! 
Mark D. Cipolle, M.D., trauma 
surgeon, has been named acting 
medical director of flight operations 
(University MedEvac). George E. 
Moerkirk, M.D., will remain in the 
role as chief of the Division of Pre-
Hospital Emergency Medical Services. 
In this capacity, he will continue to 
provide training to pre-hospital 
personnel and represent the hospital on 
the Emergency Medical Services 
Council. 
Tx~, a portable oxygen unit 
developed by Peter H. Goldman, 
M.D., family practitioner, has been 
selected by the National Safety 
Council's Lifeguard Training Program, 
and will be used for instruction in its 
Supplemental Oxygen Support (SOS) 
course. The SOS course was 
developed around this product which is 
currently being used by many aquatic 
facilities, including Wildwater 
Kingdom. 
Michael W. Kaufmann, M.D., 
Chairperson, Department of 
Psychiatry, was recently nominated by 
the Lehigh Valley Psychiatric Society 
as Councilor at Large. 
helping the hospital define the roles 
and activities of the evolving 
Community Health function at the 
hospital. 
The search committee is chaired by 
Michael W. Kaufmann, M.D., 
Chairperson, Department of 
Psychiatry. 
Thomas D. Meade, M.D., orthopedic 
surgeon, recently set two personal best 
free-style records and was a member of 
a record setting 200 yard free-style 
relay at The Mastors Swim 
Championship meet held recently at 
Rutgers University. 
LaiTy N. Merkle, M.D., chief, 
Division of Endocrinology/Metabolism, ) 
was recently inducted as a Fellow in 
the American College of 
Endocrinology at the annual meeting in 
New Orleans, La. 
Michael D. Pasquale, M.D., trauma 
surgeon, was appointed Medical 
Director for the Trauma Transitional 
Unit (TTU), formerly 5A, at Cedar 
Crest & I-78. In this position, he will 
work with the nursing staff, 
technicians, therapists, and physicians 
utilizing the unit to develop standards 
and protocols aimed at promoting the 
highest quality care. He will also head 
an educational program for the TTU 
staff. 
Barry A. Ruht, M.D., orthopedic 
surgeon, waS recently elected a Fellow 
in the American Academy of 
Orthopaedic Surgeons. ) 
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Publications, Papers and Presentations 
Indru T. Khubchandani, M.D., colon 
and rectal surgeon, was invited to 
parpcipate in the Third Biennial Course 
and International Meeting of the 
Coloproctology in Ivrea (Torino), Italy 
from March 24-26. Dr. Khubchandani 
chaired a session on Complicated 
Problems in Colon and Rectal 
Surgery and presented actual case 
reports to a panel of professors and 
chairmen of departments of Colon and 
Rectal Surgery from various countries 
including Sweden, Brazil, Denmark, 
Italy, England, and Egypt. He also 
chaired a panel on Minimally Invasive 
Surgery. 
Later in the week, Dr. Khubchandani 
lectured at the University of Genoa, 
Italy, and spoke about The Options 
for Removal of Rectal Cancer by 
Less Than Conventional Radical 
Procedures. He also lectured at the 
University of Catania in Sicily where 
he spoke about Performance of 
Anorectal Surgery in Ambulatory 
Fashion. The final stop was at 
Syracuse, Sicily, where Dr. 
Khubchandani detailed the progress in 
colorectal surgery, including 
endoscopic and laparoscopic 
procedures. 
Thomas D. Meade, M.D., orthopedic 
surgeon, recently presented Ob, My 
Aching Back during a free public 
lecture sponsored by the Health 
Promotion and Disease Prevention 
Department and the Chronic Disease 
Education Committee of Lehigh Valley 
Hospital. 
Dr. Meade also co-authored an article, 
Knee Joint Contact Pressure 
Decreases After Chronic 
Meniscectomy Relative to the Acutely 
Meniscectomized Joint: A 
Mechanical Study in the Goat, which 
was published in the Jou17Uil of 
Orthopaedic Research, The Jou17Uil of 
Bone and Joint Surgery, Inc., Volume 
11, 1993, pp. 796-804. 
George M. Perovich, Ed.D., 
psychologist, presented Exposure to 
Toxins: Use of Neuropsychological 
Tests in Conjunction with Other 
Diagnostic Techniques at the 
American College of Forensic 
Psychology lOth Annual Symposium 
held May 12-15 in Montreal, Canada. 
Charles J. Scagliotti, M.D., general/ 
trauma surgeon, presented a case 
report on Appendiceal Cancer 
Treated Laparoscopically at the 
annual meeting of the Society of 
Laparoendoscopic Surgeons held 
recently in Orlando, Fla. Also at the 
meeting, Clark Gerhart, M.D., 
surgical resident, presented his paper, 
Technique for Laparoscopic Vertical 
Banded Gastroplasty, which was co-
authored by Peter F. Rovito, M.D., 
general surgeon. They have submitted 
their paper for publication to the 
Jou17Uil of the American College of 
Surgeons. Dr. Gerhart also presented 
preliminary data on Open versus 
Laparoscopic Colon Resection: Are 
Specimens the Same? Richard C. 
Boorse, M.D., general surgeon, is co-
investigator of this ongoing study. 
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Upcoming Seminars, Conferences and Meetings 
Regional Symposium Series V 
Obstetrics and Gynecology - Joseph 
A. Miller, M.D. Resident Research 
Day will be held on Friday, June 10, 
from 8 a.m. to 4:20p.m., in the 
Auditorium of Lehigh Valley Hospital, 
17th & Chew. 
Obstetricians, gynecologists, family 
practitioners, nurses, residents, 
students, and other health care 
professionals interested in an update in 
obstetrics and gynecology will benefit 
from this program. 
At the completion of the program, 
participants should be able to: 
• describe signs and symptoms, 
diagnosis, and treatment for urinary 
incontinence; and 
• discuss current treatment modalities 
for hypertensive disorders in 
pregnancy. 
Chronic Fatigue Syndrome will be 
held on Saturday, June 11, from 7:30 
a.m. to 12:30 p.m., in the Auditorium 
of Lehigh Valley Hospital, Cedar Crest 
& 1-78. 
Physicians, nurses, and other health 
care professionals concerned with 
chronic fatigue syndrome will benefit 
from the program. 
At the completion of the program, the 
participant should be able to: 
• diagnose and manage patients with 
chronic fatigue syndrome; 
• discuss new insights related to this 
disbrder; and 
• have a more comprehensive clinical 
approach to patients with fatigue. 
For more information, please contact 
Human Resource Development at 402-
4609. 
Ethics Committee Program 
CPR and DNR: Have We Got the 
Cart Before the Horse?, a spirited 
discussion sponsored by the Ethics 
Committee, will be held on Thursday, 
May 26, at noon, in the Auditorium of 
Lehigh Valley Hospital, Cedar Crest & 
1-78. 
Presenters include Kevin J. Farrell, 
M.D., trauma/general surgeon; 
Alexander D. Rae-Grant, M.D., 
neurologist; and Stephen E. Lammers, 
Ph.D., Ethics consultant. 
For more information, contact Gale 
Brunst in the Critical Care Office at 
402-8450. 
Medical Grand Rounds 
Transplantation in the Lehigh Valley 
- An Update will be presented by 
Craig R. Reckard, M.D., chief, 
Section of Transplantation Surgery, on 
Tuesday, May 31, at noon in the 
Auditorium of Lehigh Valley Hospital, 
Cedar Crest & 1-78. 
The Medical Grand Rounds Video 
Series may be borrowed from the 
Department of Medicine at Cedar Crest 
& 1-78. Physicians who watch these 
tapes may claim one hour of Category 
2 CME credit. 
For more information or to arrange 
viewing of a video, contact the 
Department of Medicine at 402-8200. ) 
Page 10 
Department of Pediatrics 
Puzzling Cases for the Professor will 
be presented by Patrick Pasquariello, 
M.D., Director, Diagnostic Center, 
Children's Hospital of Philadelphia, on 
Friday, May 20. 
Hemolytic Uremic Syndrome will be 
presented by Mary Moran, M.D., 
Diagnostic Referral Center, St. 
Christopher's Hospital for Children, on 
Friday, June 3. 
DDA VP will be presented by Richard 
Caesar, M.D., Urology Section, St. 
Christopher's Hospital for Children, on 
Friday, June 17. 
The above Pediatric conferences will 
begin a noon in the Auditorium of 
• For Sale or Lease - Springhouse Professional 
Center, 1575 Pond Road. Ideal for physician's 
office. Approximately 1 ,000 sq. ft. 
• For Sales or Lease -- Medical/ Professional three-
story office building at 1730 Chew Street, 
Allentown. Excellent condition with recent 
renovations. Approximately 8,800 sq. ft. for single 
or multiple specialty practice. Includes long-term 
parking lease at Fairgrounds. Potential telephone 
and dictations systems. 
• For Sale - Office building at Northeast corner of 
19th and Turner Streets in Allentown. Upper level -
2,400 + sq. ft., large waiting room, two large 
consultation rooms, five exam rooms, etc. Lower 
level - 2,300 + sq. ft. Parking Jot for 1 8 oars. 
• For Lease - Office to sublet on Monday, Tuesday, 
Thursday, and Friday. 950 sq. ft. Common waiting 
area. Lakeside Professional Building, Quakertown. 
• For Lease -- Monday time slot available in the 
medical office building on the campus of Gneden 
Huetten Memorial Hospital in Lehighton. 
• For Lease- Large, newly remodeled, completely 
furnished medical office space available for 
subleasing/time share at Cedar Crest Professional 
Park. Top of the line telephone system. 
Transcription and computer system with electronic 
billing available. 
Lehigh Valley Hospital, 17th & Chew. 
For more information, contact Beverly 
Humphrey in the Department of 
Pediatrics at 402-2410. 
Psychiatric Grand Rounds 
Chronic Pain and the Disability 
Epidemic will be presented by Gerald 
Aranoff, M.D., Associate Clinical 
Professor, Tufts Medical School, and 
Director, Boston Pain Center, on 
Thursday, May 19, from noon to 1 
p.m., in the Auditorium of Lehigh 
Valley Hospital, 17th & Chew. 
As lunch will be provided, pre-
registration is requested by calling the 
Department of Psychiatry at 402-2810. 
• For Lease -- Slots are currently available for the 
Brown Bag suite at Kutztown Professional Center. 
Ideal for satellite location. 
• For Lease - Medical-professional office space 
located on Route 222 in Wescosville. Two 1 ,000 
sq. ft. offices available or combine to form larger 
suite. 
• For Lease - Medical office space located in 
Peachtree Office Plaza in Whitehall. One suite with 
1,500 sq. ft. (unfinished - allowance available), and 
one 1 ,000 sq. ft. finished suite. 
• For Lease - Specialty practice time-share space 
available in a comprehensive health care facility. 
Riverside Professional Center, 4019 Wynnewood 
Drive, Laurys Station. Half- or full-day slots 
immediately available. 
• For Lease - Professional office space available in 
an established psychology and psychotherapy 
practice at 45 North 13th Street, Allentown. Large, 
warm Victorian building in a relaxed atmosphere. 
Secretary and billing available and included in some 
leases. Furnished or unfurnished full offices and 
sublets available. Utilities included. 
For more information or for assistance in finding 
appropriate office space to meet your needs, 




The Who's New section of Medical 
Staff Progress Notes contains an 
update of new appointments, address 
changes, newly approved privileges, 
etc. Please remember that each 
department or unit is responsible for 
updating its directory, rolodexes, and 
approved privilege rosters. 
Medical Staff 
Appointment 
Michael J. Greenberg, MD 
Radiation Medicine Associates 
Pocono Cancer Center 
231 E. Brown Street 
East Stroudsburg, P A 18301 
(717) 476-3488 
Department of Radiation Oncology 
Provisional Consulting 
Susan J. Kucirka, MD 
Riverside Dermatology Associates 
(Terry I. Robbins, MD) 
Riverside Professional Center 
Route 145 Box P 
Laurys Station, PA 18059 
(610) 261-1115 
Department of Medicine 
Division of Dermatology 
Provisional Referring 
Bentley A. Ogoke, MD 
Lehigh Valley Pain Management 
(Y asin N. Khan, MD) 
1251 S. Cedar Crest Blvd. 
Suite 102B 
Allentown, PA 18103 
(610) 402-8216 
Department of Anesthesiology 
Provisional Active 
Judith R. Pryblick, DO 
(solo) 
1901 Hamilton Street 
Suite 2 
Allentown, PA 18104 
(610) 437-7181 
Department of Family Practice 
Provisional Referring 
Bernard D. Servagno, DMD 
(solo) 
623 W. Union Blvd. 
Suite 3 
Bethlehem, PA 18018 
(610) 882-9910 
Department of Dentistry 
Division of Prosthodontics 
Provisional Active 
Additional Privileges 
J. Patrick Kleaveland, MD 
Department of Medicine 
Division of Cardiology 
Active 
Transluminal Extraction Catheter 
Atherectomy (TEC) 
Edward M. Mullin, Jr., MD 
Department of Surgery 
Division of Urology 
Active 
Collagen Implantation Privileges 
Margaret S. Tretter, DO 
Department of Medicine 
Division of General Internal Medicine 
Provisional Active 
Swan-Ganz Catheter Placement 
Change of Status 
David D. Marvl, MD 
Department of Psychiatry 





William S. Berg, DPM 
No longer associated with East Penn 
Podiatry Associates 
A~dress and Telephone 
Number Changes 
WilliamS. Bera, DPM 
Fleetwood Medical Center 
P.O. Box 425 
805 N. Richmond Street 
Fleetwood, PA 19522 
(610) 944-6537 
Howard E. Hudson, Jr., :MD 
Fairgrounds Anesthesia Associates, PC 
400 N. 17th Street, Suite 205 
Allentown, PA 18104 
(610) 821-0750 
(610) 821-9099- FAX 
Martin D. Misenhimer, :MD 
5300 KidsPeace Drive 
Orefield, PA 18069 
(610) 799-8000 
New Fax Number 
Deparbnent of Famlly Practice 
Headley S. White, Jr., MD 




















Clinical Departments AI _$ 
Alphonse Maffeo,.M.D., Chairman, Anesthesiology~ 
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Guidelines on Preadmission Testing of Elective Surgery Patients Without Significant 
Underlying Disease 
As a component of our review of clinical utilization of testing, we have identified preadmission testing of 
elective surgical patients as an opportunity where we can reduce costs and not adversely effect prudent patient 
management. We hope to limit unnecessary testing of young healthy patients while meeting the standards set by 
KePRO for elective surgery patients. We are aware that some testing is a result of KePRO citations in the past 
and have reviewed requirements set by KePRO as well as published "industry" standards used at other tertiary 
care hospitals. We believe that by establishing a hospital advisory, we will set a standard for reference should 
KePRO question a decision. 
The recommendation below is a combination of protocols and standards from the University of Chicago 
(Roisen), Mayo Clinic, and KePRO for elective surgery patients without significant underlying disease. 
AGE/MALE 




Age 50-64 X 
Age ~65 X ± X 
AGE/FEMALE 
Hgb X-ray ECG 
Neonates ( <6mo.) X 
Age <40 ± 
Age 40-49 ± 
Age 50-64 X X 
Age ~65 X ± X 
( ± - use clinical judgement) Page 14 
Page 2 
These recommendations apply to patients undergoing all anesthetics: general, regional or blocks, and local with 
sedation. 
If you order one of these studies, the folloWing time frames prior to surgery apply: 
Hemoglobin - Within 1 month. Not required for patients under 49 years old with local anesthesia. 
ECG - Within 12 months; within 3 months for cardiovascular disease. 
X-ray -Not required on healthy patient. Within 1 month for patients with respiratory or cardiovascular 
disease. 
Documentation of test results from a CLIA certified lab should exist in the chart, but testing at laboratories 
other than Lehigh Valley Hospital need not be repeated. 
Also, please remember to try to schedule all elective surgery PAT more than 72 hours prior to admission since 
work performed within 72 hours of admission is rolled into the DRG hospital expense for medicare patients. 
DGB:tjw 
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Improving the Diagnostic Efficiency of Laboratory 
Tests 
In last month's newsletter, we introduced 
the concepts of diagnostic sensitivity (the 
likelihood a test will be positive in a 
patient with the disease) and specificity 
(the negativeness of a test in a patient free 
of the disease). These concepts were used 
to evaluate the performance of the newly 
introduced mass molecule CKMB test. 
Also discussed was how these concepts 
were used to establish a reference range 
for this MCKMB test. In this issue, the 
interrelationship between sensitivity and 
specificity will be compared and then used 
to show how the diagnostic efficiency of a 
laboratory test can be improved by the 
physician. 
If one studied patients admitted to the 
coronary care unit with the diagnosis of 
MI based on history, EKG findings and 
MCKMB results, some would have 
ENZYME TEST 
a MI and some would not have had a MI. 
It is impossible to select a cutoff reference 
interval for the MCKMB test that would 
afford complete discrimination between the 
two groups. At any reference range one 
must sacrifice sensitivity for specificity and 
vice-versa. Herein lies the major shortfall 
of laboratory diagnosis because few tests 
are sensitive and specific at the same time. 
Looking at the results of multiple 
laboratory tests improves predictive value 
somewhat, but the trade off between 
sensitivity and specificity always remains. 
There are no perfect tests or combination 
of tests with 100% sensitivity and 100% 
specificity. An example of how they are 
related is shown in the following table 
which demonstrates this inverse 
relationship between sensitivity and 
specificity. 
Prevalence of MI SO% 
Reference Sensitivity % Specificity % Predictive Value 
Value Positive Test % 
2 100 60 71 
4 95 75 79 
6 85 85 85 
8 70 95 93 
10 50 100 100 
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The type of disease being diagnosed by a 
test determines whether it is desirable to 
maximize sensitivity or specificity. A 
clinician who obtains a history and 
physical should be able to have a combined 
sun of sensitivity and specificity of~ 
to 170% for the diagnosis of most 
diseases. This means that the laboratory 
test that is ordered to diagnose the disease 
should perform better than 170% if it is to 
be used for a diagnosis and not just for 
confirmation of the diagnosis. 
Finally, the following table demonstrates 
the change in predictive value that occurs 
for a test with changing prevalence of 
disease. It can be readily seen that a 
particular test has a higher predictive value 
when the disease occurs with a higher 
prevalence. This explains why a ~ 
diagnostic test frequently fails as a 
screening test. When clinical judgment is 
used in ordering laboratory tests, the 
patient, suspected of having a particular 
disease, is placed in a new population with 
a high prevalence or probability of disease. 
This concept is shown in the table below. 
Predictive value as a function of disease 
prevalence for a test with 95% sensitivity 
and 95% specificity. 







If this test were the MCKMB test for the 
diagnosis of a MI, we can compare the 
performance of this test in the chest pain 
clinic (5% prevalence of MI) to that in the 
coronary care unit (50% prevalence of 
Ml). When used in the clinic 50% of the 
patients with a positive test would have a 
MI the remaining 50% would be false 
positives. This same enzyme test used in 
the CCU exhibits a predictive value of 
95% with only 5% of the positive test 
results being false positives. 
It is apparent from the above discussion 
that a physician can significantly improve 
the diagnostic performance of a laboratory 
test with a good history and physical that 
places the patient in a category with higher 
probability of disease. 
For tests used in screening for a disease 
(i.e., neonatal metabolic screening & HIV) 
the predictive value is low as is the sum of 
sensitivity plus specificity. Therefore the 
performance of the test is poor. By 
employing these predictive value concepts 
we can set ~ur testing parameters for the 
screening test to maximize sensitivity. 
This means that all patients with the 
disease test positive but so do a number of 
patients who are !liB gositives. A second 
confirmation test designed to maximize 
specificity is used to separate the true 
positives from the false positives. 
However this is not without additional cost 
to the medical system. 







In summary, the statistical discussion of 
testing as presented in the last three 
newsletters suggests there is no free lunch 
when it comes to laboratory testing. All 
criteria pertaining to a test must be 
identified and maximized to ensure the 





P & T HIGHLIGHTS 
The following action were taken at the April 11, 1994 Pharmacy and 
Therapeutics Committee Meeting - James A. Giardina, Director of Pharmacy 
FORMULARY ADDITION REQUESTS 
AFFECTING THE BRAIN 
Risperidone (Risperdal, Janssen) is a 
mixed serotonin-dopamine antagonist 
which is approved for the treatment of 
psychotic disorders. At low doses 
resperidone is a selective serotonin 5-
HT[2] receptor antagonist while at higher 
doses it antagonizes dopamine-D[2] 
receptors. As a central dopamine-D[2] 
antagonist, it is less active than 
haloperidol. Risperidone was developed on 
the hypothesis that combining both 
serotonin and dopamine receptor inhibition 
would result in an improved therapeutic 
response in schizophrenia. It is hoped that 
it will improve both positive and negative 
symptoms in psychotic patients without 
significant extrapyramidal symptoms. At . 
low doses, it is thought to be effective in 
schizophrenic patients with predominantly 
negative symptoms, while at higher doses, 
it exerts activity on both positive and 
negative symptoms. 
Risperidone is well absorbed and 
bioavailability is unaffected by food. It 
undergoes extensive hepatic metabolism 
via the cytochrome P450-IID6 System to 
an equally active metabolite. The 
combined products have an elimination 
half-life of 20 hours and are excreted 
without further degradation; hence, 
clearance is reduced in renally impaired as 
well as elderly patients. 9% of patients in 
clinical trials had therapy discontinued due 
to side effects, which are dose related and 
more likely when daily doses exceed 6mg. 
The most frequently reported ones were 
extrapyramidal reactions, nausea, 
dizziness, hyperkinesia, somnolence, 
constipation and rhinitis. A transient 
decrease in blood pressure and heart rate, 
postural hypotension, and syncope have 
been reported, especially during the initial 
dose titration period. Both risperidone and 
its metabolite appear to lengthen the QT 
''interval in some patients and may increase 
the risk of torsades de pointes, particularly 
in patients with bradyc~rdia, electrolyte 
~m.balance, or in patients on drugs that 
prolong the QT interval. Drug interactions 
include agents such as quinidine, which 
interferes with cytochrome 
P450-IID6 metabolism and interferes with 
the conversion to the metabolite. 
Risperidone is unlikely to interfere with 
other agents metabolized by the 
cytochrome P450-IID6 system due to its 
weak affinity for the enzyme. Chronic 
administration of carbamazepine may 
increase the clearance of ·risperidone while 
chronic clozapine therapy may reduce the 
clearance. It may enhance the effects of 
some hypotensive agents and may 




' dopamine agonists. It should be used 
cautiously with other centrally active 
agents and alcohol. 
It is recommended that therapy begin at 
1mg twice daily with a 1mg twice daily 
increase on days 2 and 3. Further dosage 
adjustments of 1mg twice daily are 
recommended at weekly intervals with the 
Venlafaxine (Effexor, Wyeth) is a bicyclic 
antidepressant that inhibits neuronal uptake 
of serotonin, norepinephrine, and to a 
lesser extent, dopamine. It is indicated for 
the treatment of depression. Its selectivity 
is serotonin > norepinephrine > 
dopamine. Animal studies predict a more 
rapid onset of action than tricyclic 
antidepressants. 
Venlafaxine is well absorbed with food 
having no effect on absorption, it is 
rapidly converted via a saturable metabolic 
pathway (first-pass effect) to an active and 
other metabolites. No other metabolism 
occurs prior to excretion in the urine. 
There are few studies available to date 
showing efficacy as compared to other 
antidepressants. Adverse effects include 
anorexia, dizziness, blurred vision and 
sexual dysfunction. Many are dose related 
and largely due to serotonin activity. 
Tachycardia and hypertension have been 
reported and routine blood pressure 
monitoring is recommended with dosage 
reduction/ discontinuation recommended in 
patients with sustained, increased blood 
pressure. 
maximum· recommended dose being 6mg 
twice daily. Dose initiation, adjustment 
and maximum are halved in elderly and 
debilitated patients, patients with severely 
impaired renal or hepatic status, and 
patients predisposed to hypotension. 
Risperidone comes as 1, 2, 3 and 4mg. 
Annual costs of therapy are projected at 
$1900-2400. 
Little information is available about 
specific interactions with a 
recommendation to avoid concomitant or 
therapy within 14 days of MAO inhibitors. 
Use of other antidepressants is not 
encouraged and concurrent CNS 
depressants may result in additive or 
synergistic sedation. Venlafaxine has not 
been studied in pregnancy, lactation or 
children. The initial dose is recommended 
as 75mg daily in two or three divided 
doses. Incremented adjustments of 
75mg/day are recommended at 4 day 
intervals to a total of 225mg. The 
maximum recommended dose in severely 
· depressed patients is 375mg/day. Dosage 
reduction is recommended in hepatically 
and renally impaired patients. In 
hemodialysis patients, the dose should be 
reduced by 50% and withheld until after 
dialysis. Venlafaxine comes as 25, 50, 75 
and lOOmg tablets. Venlafaxine was 
added for a 6 month therapeutic evaluation 
to see if it does have a quicker onset of 
activity as well as whether it will lessen 
the need for augmentation therapy because 
of its unique pharmacologic profile. 
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Pergolide (Permax, Lilly) is a semi-
synthetic ergot alkaloid which is stated to 
be more potent and longer acting than 
bromocriptine. It is indicated as an 
adjunct to traditional therapy in 
Parkinson's Disease and may offer value 
in preventing, reducing or treating 
fluctuating or "on/ off" response. It is a 
centrally acting dopamine agonist which 
stimulates both D 1 and D2 receptors. 
Once converted to dopamine, levodopa 
stimulates both D1 and D2 receptors, 
whereas bromocriptine stimulates only D2 . 
receptors. 
Oral absorption is rapid and followed by 
extensive first-pass metabolism to many 
active metabolites, which are excreted in 
the urine (55%), feces (40%) and lungs 
(5%). It has a duration of action of 
greater than 24 hours. The most common 
adverse reactions to pergolide are nausea, 
light-headedness, dry mouth, drowsiness, 
orthostatic hypotension, confusion, 
hallucinations and dyskinesias. Side 
effects are dose related as with the other 
anti-parkinson agents. In patients taking 
pergolide who are able to reduce levodopa 
dosage, side effects may be decreased. 
Caution should be exercised in patients 
prone to dysrhythmias. 
Pergolide has not been studied in 
pregnancy, lactating women or children. 
Dopamine antagonists (neuroleptics, 
metoclopramide) may diminish its activity. 
Dosage should be started at 0.05mg for the 
first 2 days with escalation by 0.1-
0.15mg/day every 3rd day over the next 
12 days. Doses may then be adjusted by 
0.25mg/day every third day until 
therapeutic response is achieved. The 
average therapeutic dose is 3mg with an 
average concurrent daily dose of 
levodopa/carbidopa of 650mg (as 
levodopa). Pergolide comes as 0.05, 0.25 
and 1mg tablets. 
DRUG USE EVALUATION (Dl!E) CORNER 
INJECTABLE H2RA USE 
Pharmacy presented the most recent 7 
month report together with the full year's 
report on converting IV H2RAs to PO. 
The study focused on patients who were 
currently receiving at least two scheduled 
(not PRN) medications orally and 
recommendations for conversion to the PO 
route. 91% of the conversion 
recommendations were followed during the 
last 7 months. Due to the nature of the 
study, there was an inherent 
lag time from Pharmacist recommendation 
to Physician action with results showing 
that 50% were changed in 1 day, 7 5 % in 3 
days, and 91% in 5 days. Given the rate 
of acceptance, and the potential savings 
involved, the Committee approved 
automatic conversion of Famotidine IV to 
Nizatidine PO for patients who have 
received and tolerated at least 2 oral meds 
for a minimum of 24 hours. The tentative 
start date for the automatic conversion of 





A comprehensive review of Alteplase (t-PA) prescribing from May 93 to March 94 was 
performed to assess therapy complications. 91 of 92 patients received either standard or 
accelerated dosing. 
Table 1 -Review of 91 patients tPA (May 93 - March 94) 
# of Patients (%) # of Patients (%) 
Standard Accelerated 
Number of patients 54 (59%) 37 (41 %) 
Patients L. 75 y.o. 2 5 
Patients < 65 Kg 2 5 
Heparin Use 
Dose 
No bolus 12 (22%) 4 (11 %) 
5,000 unit bolus 38 (78%) 28 (76%) 
> 5,000 unit bolus 1 (2%) 5 (14%) 
Timing 
with tPA 36 (67%) 29 (78%) 
after tPA 18 (33%) 8 (22%) 
Adverse Clinical Events 
(% incidence of total# patients) 
Fatal intracerebral bleed (1 %) 0 1 
All Intracerebral bleeds ( 4%) 1 3 
Non-hemorrhagic stroke (0%) 0 0 
Recurrent ischemia ( 10%) 7 2 
Other bleeding (13%) 5 7 
Patients requiring transfusion (9%) 4 4 
Number patients (%) requiring further cardiac interventions 
PTCA 22 (41 %) 13 (35%) 
CABG 9 (17%) 5 (14%) 
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The two dosing regimens are defined as follows: 
Standard Dosing Regimen 
Patient weight 2. 65Kg lOOmg Usual Dose 
Patient weight < 65 Kg 1.25mg/Kg 
for a 70Kg 
Patient 
Bolus over 1-2min 6-10% 6mg 
Total over next 58-59 min 54-50% 54mg 
Total over second hour 20% 20mg 
Total over third hour 20% 20mg 
Accelerated (Front loaded) Dosing Regimen from GUSTO Trial 
Patient weight 2. 65Kg lOOmg Usual Dose 
Patient weight < 65Kg Weight adjusted dose 
for a 70Kg 
Patient 
Bolus 15mg 15mg 
total over first 30 min 0.75mg/Kg (not to 50mg 
exceed 50mg) 
total over next 60 min 0.35mg/Kg (not to 35mg 
exceed 35mg) 
pt\41194.min 
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